Class II
FDA
Nova Biomedical StatStrip Glucose Hospital Meter recalled over See official notice
Nova Biomedical StatStrip Glucose Hospital Meter was recalled on October 5, 2026 because of see official notice. It is a Class II recall (possible temporary or reversible harm). Affected area: ID. Do not eat this product. Check the official FDA notice for affected lot codes and instructions.
HazardSee official notice
Risk levelClass II
Affected area1 states
CategoryFood
What to do
Do not eat this product. Check the official FDA notice for affected lot codes and instructions.
Confirm the details against the official FDA notice before acting.
Does this affect you?
Check the product in your home against the recalled item:
- Product as filed
- Nova Biomedical® — Global Medical Device Correction for StatStrip® Glucose Hospital Meter
The notice lists no UPC or lot code. Match the brand, product name and package size against the official FDA notice.
Full recall details
- Reason for recall
- WALTHAM, Mass., October 5, 2026 – Nova Biomedical initiated a global Medical Device Correction on July 24, 2026, for the StatStrip® Glucose Hospital Meter System due to a software issue that may cause a glucose result to be associated with the wrong patient.
- Hazard class
- Class II — possible temporary or reversible harm
- Recalling company
- Nova Biomedical®
- Recall type
- Voluntary
- Quantity
- Distribution
- While working on resolution to the patient ID issue, Nova is providing the following recommendations to end users: To mitigate the risk of glucose results being assigned to the wrong patient’s medical record, Nova recommends the use of patient validation and operator log o software configurations available in current Statstrip Glucose Hospital meter system and NovaNet middleware.
Compiled from the official FDA record by our data rules — how we build these pages. Spotted an error? Report it.
Get recalls in your inbox
A short email when a serious new U.S. food recall is posted. Free. Unsubscribe anytime.
Want alerts only for your allergens or brands? Build a watchlist →